DK3962494T3 - Pulserende gnrh-administration til behandling af kognitive forstyrrelser - Google Patents

Pulserende gnrh-administration til behandling af kognitive forstyrrelser

Info

Publication number
DK3962494T3
DK3962494T3 DK20722577.2T DK20722577T DK3962494T3 DK 3962494 T3 DK3962494 T3 DK 3962494T3 DK 20722577 T DK20722577 T DK 20722577T DK 3962494 T3 DK3962494 T3 DK 3962494T3
Authority
DK
Denmark
Prior art keywords
pulsated
treatment
cognitive disorders
gnrh administration
gnrh
Prior art date
Application number
DK20722577.2T
Other languages
Danish (da)
English (en)
Inventor
Vincent Prevot
Andrea Messina
Paolo Giacobini
Valérie Leysen
Lozano Maria Manfredi
Original Assignee
Inst Nat Sante Rech Med
Univ Lille
Centre Hospitalier Regional Et Univ De Lille
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Univ Lille, Centre Hospitalier Regional Et Univ De Lille filed Critical Inst Nat Sante Rech Med
Application granted granted Critical
Publication of DK3962494T3 publication Critical patent/DK3962494T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK20722577.2T 2019-04-30 2020-04-29 Pulserende gnrh-administration til behandling af kognitive forstyrrelser DK3962494T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19305550 2019-04-30
PCT/EP2020/061943 WO2020221821A1 (en) 2019-04-30 2020-04-29 Pulsative gnrh administration for treating cognitive disorders

Publications (1)

Publication Number Publication Date
DK3962494T3 true DK3962494T3 (da) 2026-04-07

Family

ID=66625872

Family Applications (1)

Application Number Title Priority Date Filing Date
DK20722577.2T DK3962494T3 (da) 2019-04-30 2020-04-29 Pulserende gnrh-administration til behandling af kognitive forstyrrelser

Country Status (6)

Country Link
US (1) US20220202895A1 (cg-RX-API-DMAC7.html)
EP (1) EP3962494B1 (cg-RX-API-DMAC7.html)
JP (1) JP7779739B2 (cg-RX-API-DMAC7.html)
DK (1) DK3962494T3 (cg-RX-API-DMAC7.html)
ES (1) ES3067563T3 (cg-RX-API-DMAC7.html)
WO (1) WO2020221821A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022136417A1 (en) 2020-12-22 2022-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Pulsative gnrh administration for treating food intake related disorders
AU2023332041A1 (en) 2022-09-02 2025-02-20 Leibniz-Institut Für Immuntherapie (Lit) THERAPEUTIC USE OF THE miR155 SNP rs377265631

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0158683B1 (de) 1984-04-14 1988-10-05 Ferring Biotechnik GmbH Vorrichtung zum intermittierenden Applizieren flüssiger Arzneimittel
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
US5013293A (en) 1987-05-28 1991-05-07 Drug Delivery Systems Inc. Pulsating transdermal drug delivery system
US20080171736A1 (en) * 2004-12-23 2008-07-17 Gregory Christopher W Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists
WO2007041386A2 (en) 2005-09-30 2007-04-12 Vyteris, Inc. Pulsatile delivery of gonadotropin-releasing hormone from a pre-loaded integrated electrotransport patch
WO2014110549A1 (en) * 2013-01-14 2014-07-17 The General Hospital Corporation Methods and assays relating to rnf216
WO2014179139A2 (en) * 2013-04-30 2014-11-06 Albert Einstein College Of Medicine Of Yeshiva University TREATMENT OF AGING EFFECTS BY GONADOTROPIN-RELEASING HORMONE, NEUROGENESIS OR BRAIN IKK-β/NF-κΒ INHIBITION
WO2017182580A1 (en) 2016-04-20 2017-10-26 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for the diagnosis and the treatment of reproduction-related disorders and methods for contraception
CN108837143B (zh) * 2018-09-29 2022-03-01 南华大学 曲普瑞林的应用

Also Published As

Publication number Publication date
JP7779739B2 (ja) 2025-12-03
US20220202895A1 (en) 2022-06-30
WO2020221821A1 (en) 2020-11-05
EP3962494A1 (en) 2022-03-09
JP2022533011A (ja) 2022-07-21
ES3067563T3 (en) 2026-05-22
EP3962494B1 (en) 2026-03-04

Similar Documents

Publication Publication Date Title
DK3570844T3 (da) Azolopyrimidin til behandlingen af kræftrelaterede lidelser
DK3743070T3 (da) Forbindelser til behandling af kinaseafhængige lidelser
DK3673080T3 (da) Antisense-oligomerer til behandling af lidelser og sygdomme
DK3501542T3 (da) Esketamin til behandling af depression
DK3785733T3 (da) Farmaceutisk sammensætning til behandling af autisme
DK4259796T3 (da) Terapeutiske midler til behandlingen af neurodegenerative lidelser
DK3277815T3 (da) Oligonukleotidforbindelser til behandling af præeklampsi og andre angiogene lidelser
IL262852A (en) Treatment of complement-mediated disorders
DK3548061T3 (da) Behandling af neurologiske sygdomme
IL272601A (en) Pharmaceutical compositions for the treatment of ophthalmic conditions
DK3439661T3 (da) Fremgangsmåder til behandling af øjenlidelser
DK3256466T3 (da) 1-heterocyclyl-isochromanylforbindelser og analoger til behandling af cns-forstyrrelser
PL3573620T3 (pl) Kompozycje do leczenia nadciśnienia
DK3578562T3 (da) L-valinatamidbenzoxaborolderivater til behandling af parasitiske sygdomme
DK3724173T3 (da) Forbindelser til behandling af neuromuskulære lidelser
DK3585808T3 (da) Modificerede serpiner til behandlingen af bradykinin formidlet sygdom
IL280227A (en) Arimoclomol for treating glucocerebrosidase associated disorders
IL283503A (en) Combined treatment of primary central nervous system lymphoma
DK3419672T5 (da) Genterapi til behandling af retinal degenerationssygdom
IL263080B (en) Treatment of neurological disorders
DK3403674T3 (da) Farmaceutiske sammensætninger til behandling af smerte
IL285765A (en) Therapeutic uses of dulaglutide
DK3743043T3 (da) Farmaceutiske sammensætninger til behandling af post-operative smerter
DK3519050T3 (da) Sammensætninger til behandling af oftalmiske sygdomme
DK3897655T3 (da) 3beta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-on til anvendelse i behandlingen af kognitive lidelser